Table II.
Model | Principal components obtained by cross-validation, n | R2X | R2Y | Q2 |
---|---|---|---|---|
T and L | 100 | 0.226 | 0.983 | 0.768 |
T and C | 100 | 0.182 | 0.919 | 0.361 |
L and C | 100 | 0.283 | 0.995 | 0.688 |
R2X, variation explanation in X; R2Y, variation explanation in response to Y; Q2, predicted variation capability of compound. T, tuberculous pleural effusion group; L, transudative pleural effusion group; C, malignant pleural effusion group.